Archer™ VARIANTPlex™ Expanded Solid Tumor panel
Discover key DNA signatures of multiple cancers with one panel
Efficiently detect single nucleotide variants, insertions, deletions, copy number variations, and microsatellite instability with targeted NGS of 76 relevant genes for colorectal, breast, melanoma, pancreatic, NSCLC and other pan-cancer research.
Detect confidently with Archer VARIANTPlex NGS Panels for DNA.
Talk to a technical sales expert
Learn how the VARIANTPlex Expanded Solid Tumor panel can identify key genomic alterations for your research.
Request a consultationProduct details
Panel specifications
| Specifications | |
|---|---|
| Targeted genes | 76 |
| Genomic alterations | SNVs, indels, CNVs, ITDs, MSI |
| Input nucleic acid required* | ≥10 ng |
| Recommended number of reads | 6 M |
| Hands-on time | <3.5 hours |
| Total library prep time | 1.5 days |
| Platform compatibility | Illumina® |
| Reagent format | Lyophilized or liquid |
| Supported sample types | FFPE, fresh frozen, cytology smear, FNA |
*Input mass requirements vary depending on type and quality. Unless the tumor cellularity and sample quality are high, 50 ng of FFPE-derived nucleic acid should be considered the minimum recommendation. If input is not limiting, 200 ng is recommended.
Gene targets
Interested in adding a few genes to this panel?
Customize this NGS panel by adding any of our functionally-tested designs or create a new panel that fits your exact requirements with Assay Marketplace.
Benefits
- Detect confidently—Archer’s unique outlier detection algorithm leverages position-specific data to enable variant detection even at low allele frequencies, while Archer Analysis makes providing answers easy.
- Less QNS—Anchored Multiplex PCR (AMP™) chemistry is designed for compatibility with a wide variety of sample types, including low-input and potentially degraded samples such as FFPE tissue.
- Achieve efficiency—Streamlined workflows for your lab are enabled by choice of reaction-sized lyophilized reagents or high-throughput liquid reagents, while parallel workflows across all Archer panels provide efficient genomic characterization.
- Customize content—Use Assay Marketplace to modify any panel to fit your lab's needs or start from scratch to keep up with the pace of discovery.
Ready to start?
Talk with our technical sales team. Learn how the VARIANTPlex Expanded Solid Tumor panel can identify key genomic alterations for your research.
Request a consultationResources
Frequently asked questions
Can I analyze solid tumor DNA and RNA simultaneously for comprehensive genomic profiling with Archer panels?
Yes, DNA and RNA from a single sample can be analyzed with VARIANTPlex™ and FUSIONPlex™ panels to provide a genomic profile of the cancer.
For comprehensive genomic profiling, pair the VARIANTPlex Complete Solid Tumor v2 and FUSIONPlex Pan Solid Tumor v2 panels to interrogate 511 genes for SNVs, indels, CNVs, fusions, exon-skipping, and splicing variants, as well as assessment of HRD, MSI, and TMB. Additionally, the IMMUNOVerse™ TCR panel can provide tumor-infiltrating lymphocyte information relevant for solid tumor characterization. All Archer panels have parallel workflows, allowing for streamlined comprehensive solid tumor profiling.
Can VARIANTPlex™ assays be used for somatic and germline evaluation?
Most VARIANTPlex assays can be used for both somatic and germline variant detection. However, some custom‑designed panels for germline applications may not be suitable with FFPE tissue with shorter fragment lengths.
What is the difference between Anchored Multiplex PCR (AMP™) and traditional priming methods for DNA NGS analysis?
As opposed to traditional priming methods, AMP chemistry enables tiling primers across both strands of DNA, optimally covering targeted regions for amplification and characterization of challenging, yet relevant alterations such as internal tandem duplications. Additionally, AMP chemistry uses molecular barcode adapters that bind to DNA fragments before amplification, allowing for efficient amplification of targets even from degraded or fragmented nucleic acid input, such as DNA from FFPE tissue and ctDNA from plasma.
Related products
RUO23-2305_001